Anika Therapeutics Submits Final PMA Module for Hyalofast Cartilage Repair Scaffold Despite Mixed Phase III Results
核心洞察
Anika Therapeutics (搜索) filed the final module of its Premarket Approval application for Hyalofast, a hyaluronic acid-based cartilage repair scaffold, with the FDA on October 31, 2025.
The pivotal Phase III FastTRACK trial failed to meet its co-primary endpoints for pain and function, but demonstrated statistically significant improvements in secondary endpoints including sports recreation and quality of life measures.
Post-hoc analyses revealed that 87.4% of Hyalofast patients achieved clinically meaningful pain improvements compared to 75.3% of microfracture patients at 24 months.
Anika Therapeutics (搜索) has completed its regulatory submission for Hyalofast, a hyaluronic acid-based cartilage repair scaffold, filing the third and final module of its Premarket Approval application with the FDA on October 31, 2025. The submission includes comprehensive 24-month data from the company's pivotal Phase III FastTRACK clinical trial, along with post-hoc analyses and real-world evidence from over 35,000 patients treated globally since 2009.
Mixed Results from Pivotal Phase III Trial
The FastTRACK study, initiated in 2015, was designed as a prospective, randomized, active treatment-controlled, evaluator-blinded, multicenter trial to establish superiority of Hyalofast combined with autologous bone marrow aspirate concentrate (BMAC) over microfracture for treating articular knee cartilage defects. The trial enrolled patients with symptomatic cartilage lesions and monitored outcomes for two years.
The study failed to meet its pre-specified co-primary endpoints under the original statistical framework. At 24 months, KOOS Pain scores showed an 8.11% difference favoring microfracture (p=0.81), while IKDC Function scores showed a 4.84% difference favoring Hyalofast (p=0.34), with neither result achieving statistical significance.
However, post-hoc analyses using non-parametric statistical methods revealed more favorable outcomes for Hyalofast. When analyzed without data imputation using observed data only, Hyalofast demonstrated a 23.37% improvement over microfracture in KOOS Pain scores (p=0.02) and showed superiority with an absolute difference of 4.54 points (p=0.02), both statistically significant results.
Significant Secondary Endpoint Achievements
Despite the primary endpoint challenges, Hyalofast demonstrated statistically significant improvements across multiple secondary measures. The treatment showed a 12.19-point gain in KOOS Sports and Recreation scores (p=0.01) and a 9.52-point improvement in KOOS Quality of Life scores (p=0.03) compared to microfracture. Additionally, Hyalofast outperformed microfracture in Total KOOS—a composite measure of pain and function—by 6.57 points (p=0.02).
Responder Analysis Shows Clinical Benefit
A post-hoc responder analysis revealed that significantly more patients achieved clinically meaningful improvements with Hyalofast. At 24 months, 87.4% of Hyalofast patients achieved at least a 10-point improvement in KOOS Pain versus 75.3% of microfracture patients (p=0.050). The advantage became more pronounced at higher improvement thresholds, with 83.5% of Hyalofast patients achieving 15-point improvements compared to 60.8% in the microfracture group (p=0.004).
At the highest threshold of 20-point improvement, 72.8% of Hyalofast patients responded compared to 52.6% in the microfracture group (p=0.029), demonstrating the consistency and depth of pain relief achieved with the treatment.
Study Challenges and Regulatory Context
Anika attributes the mixed primary endpoint results to several factors that impacted statistical power. The microfracture arm experienced nearly double the dropout rate of the Hyalofast arm, resulting in significant missing data due to COVID-related disruptions and patient dissatisfaction with microfracture treatment. The original statistical analysis assumed normally distributed data missing at random, which may not have been appropriate given the actual data characteristics.
"We believe the comprehensive results of the FastTRACK study reinforce Hyalofast's potential as a transformative, single-stage, off-the-shelf cartilage repair solution for patients in the U.S.," said Cheryl Blanchard, President and CEO of Anika Therapeutics (搜索). "We are proud of the robust clinical data that we presented to the FDA and we look forward to working with the FDA on our goal of bringing Hyalofast to patients in the U.S."
Global Experience and Regulatory Status
Hyalofast is currently marketed in over 35 countries and has demonstrated safety and efficacy in multiple clinical trials. The off-the-shelf, single-stage scaffold is designed to support regeneration of hyaline-like cartilage and has received Breakthrough Device Designation from the FDA. International published studies have shown positive long-term outcomes extending to 15 years.
The company's regulatory strategy leverages the significant improvements observed in secondary endpoints, including KOOS Sports and Recreation and Quality of Life measures, which have supported prior FDA approvals for cartilage repair products. The comprehensive PMA submission incorporates this clinical evidence alongside extensive real-world data from the global patient experience.